Ozempic and similar drugs have been thrust into the spotlight for their weight-loss effects, promising new research keeps finding other potential uses for it, such as treating substance use disorder. Now, a new paper describes how the drug fares in lowering risk for Alzheimer’s disease.
A new study led by researchers at Case Western Reserve University found that in patients with type 2 diabetes who were treated with semaglutide, the active ingredient in Ozempic, their risk of developing Alzheimer’s was reduced by up to 70 percent compared to those who used typical diabetes medications. Currently there is no cure for Alzheimer’s disease, and affirmation that a drug could help prevent it would add a powerful tool to our medical arsenal. The paper was published Thursday in the journal Alzheimer’s & Dementia.
